PTC Therapeutics (PTCT) reported Q1 net income late Tuesday of $10.04 per diluted share, swinging from a loss of $1.20 a year earlier.
Revenue for the quarter ended March 31 was $1.18 billion, up from $210.1 million a year earlier.
Shares of the company were up 5% in Tuesday's after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。